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Summary A doxorubicin-resistant line of B16 melanoma (B16VDXR) was obtained in vitro by continuous
exposure to increasing concentrations of doxorubicin of an in vitro line (B16V) derived from the in vivo
transplanted B16 melanoma. When injected s.c. into mice, B16VDXR exhibited histological features,
metastatic behaviour, doubling time and tumourigenic potential similar to those of the parental B16V line.
Tumours obtained by implantation of B16VDXR, however, had longer latency and permitted a longer
survival time than B16V and had, as in vitro, a higher DNA content. After i.v. inoculation, B16VDXR cells
had lower lung colonizing capability compared to B16V. B16V and B16VDXR had significantly lower
metastatic potential compared to the B16 melanoma from which they derived. Doxorubicin treatment
significantly delayed the growth of B16 and B16V transplanted s.c. and increased the life span of animals
bearing B16V. B16VDXR was resistant to doxorubicin treatment when the in vitro resistance index was
> 100. While the doxorubicin-resistance phenotype was stable in vitro for 50 passages, in vivo the resistance
phenotype was lost in 5 passages and tumours grown from s.c. inocula of mixtures of similar percentages of
sensitive and resistant cells behaved as sensitive tumours. Cis-diamminedichloroplatinum (II), although
marginally active in animals bearing B16V, was highly effective in B16VDXR bearing animals, suggesting a
collateral cis-diam*iinedichloroplatinum (II) sensitivity of the B16VDXR line. After a single i.v.
administration, doxorubicin reached initially, in the B16VDXR line, levels similar to those found in the B16
and B16V lines, but its release was faster from the resistant line in comparison with the sensitive ones.
Doxorubicin-resistance was not overcome by more frequent treatments with doxorubicin. This doxorubicin-
resistant tumour line obtained in vitro and used as a first in vivo transplant, may be a suitable metastatizing
model for in vivo study of the mechanisms of resistance and of collateral sensitivity and for screening new
drugs.
Doxorubicin (DX) is one of the most widely used
antineoplastic drugs because it exhibits considerable
activity against a broad spectrum of solid tumours
and leukaemias. Unfortunately, as for anticancer
drugs in general, tumours often are either resistant
from the outset or become so after chemotherapy.
This phenomenon, together with metastatic spread,
represents the most important obstacles which limit
the success of chemotherapy. In order to under-
stand the mechanisms involved in anthracycline
resistance, several experimental systems have been
developed both in vitro and in vivo (Biedler et al.,
1983; Dan0, 1972; Inaba et al., 1979). Most of the
in vivo studies, however, have been performed either
on leukaemias or sarcomas grown in ascitic form
and treated with i.p. administration of the drugs to
be tested, i.e. by an assay which mimics the in vitro
situation (Biedler et al., 1983; Seeber et al., 1982),
or on solid tumours whose sensitivity and resistance
to DX were tested only in in vitro assays (Giavazzi
et al., 1983). Such experimental systems, although
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very helpful for an understanding of specific
molecular events associated with acquired
resistance, may not be suitable for examining other
important factors which may influence the response
of the tumour to chemotherapy such as metastatic
spread, immunological sensitivity in addition to the
pharmacokinetics and the metabolism of the drug.
Our aim was to develop a DX-resistant solid
metastasizing tumour as a potentially useful m.O*
for defining the nature of resistance to DX in vivo,
for investigating means of circumventing DX-
resistance and for screening new non-cross resistant
drugs. We describe here the main in vivo biological
properties and the sensitivity of a B16 melanoma
line, made resistant to DX in vitro, in comparison
with those of the original tumour and with those of
an in vitro DX-sensitive line.
Materials and methods
Animals
Adult (8-10 weeks old) C57BL/6NCrl and
(C57BL/6NCrl x DBA/2NCrl)F1 (B6D2Fl) male
mice were supplied by Charles River Breeding
(9 The Macmillan Press Ltd., 1986224 F. FORMELLI et al.
Laboratories (Calco, Como, Italy). Eight to 10
animals per group were used in each experiment.
Tumour and tumour cell lines
The B16 melanoma, obtained from the Division of
Cancer Treatment of the National Cancer Institute
(Bethesda, MD, USA) was maintained by s.c.
implantation of a tumour homogenate in C57BL/6
mice (Geran et al., 1972). Detailed description of
the in vitro lines is reported in a previous paper
(Supino et al., 1986). The schematic representation
of the obtained lines is given in Figure 1. A cell line
obtained by trypsinization of B16 melanoma and
designated B16V, was maintained in medium RPMI
1640 (Flow Laboratories, Irvine, Ayrshire, UK)
supplemented with 10% foetal calf serum (Flow
Laboratories) and Fe(CN)6K3 0.03mM and
routinely subcultured twice a week. The DX-
resistant cell line, designated B16VDXR, was
obtained by continuous exposure of B16V cells to
increasing concentrations of DX starting from
5ngml1 up to 420ngml-1 in about 60 transplant
generations. These cells were cultured further either
in medium containing 420ngml- (B16VDXR) or
in drug-free medium (B16VR) for 20 passages.
B16VDXR cells, continuously exposed to
420ngml- I DX were subcultured in drug free
medium for 24h before being tested.
Drugs
DX (Farmitalia-Carlo Erba, Milan, Italy) was
dissolved in distilled water immediately before use.
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Cis-diamminedichloroplatinum (II) (cis-DDP)
(Farmitalia-Carlo Erba, Milan, Italy) was dissolved
in 0.9% NaCl.
Index ofresistance (RI) in vitro
Detailed description of the in vitro assays of levels
of resistance has been reported (Supino et al.,
1986). Briefly, cells were treated at cell seeding with
different concentrations of DX. After 72h, cells
were harvested by trypsinization and counted in a
model ZBI Kontron Coulter Counter. The RI was
evaluated as the ratio between the graphically
determined concentration causing a 50% decrease
in cell number at this time point (ID50) on the
B16VDXR cells and the ID50 on the B16V cells.
In vivo studies
All the in vivo studies were performed in B6D2F1
mice, since chemosensitivity studies on B16
melanoma were performed in this strain according
to standard, accepted procedures (Geran et al.,
1972). No differences in takes and growth rate for
this tumour were found in syngeneic C57BL/6 as
compared to semi-syngeneic B6D2Fl animals. One
million cells from B16 melanoma, B16V,
B16VDXR and B16VR lines were implanted s.c. in
a 0.2ml of RPMI 1640 in the right flank of
B6D2F1 mice. For B16 melanoma, tumour
homogenates were obtained 10 days after tumour
transplant and for the lines grown in vitro tumour
cells were obtained by brief exposure of 24h
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Figure 1 Schematic representation of induction of DX-resistant cell lines. B16V line was obtained by
trypsinization of B16 melanoma. B16VDXR was obtained by continuous exposure of B16V cells to increasing
concentrations (up to 420ngml-') of DX and maintained in medium containing 420ngmlPl DX. B16VR
was obtained from B16VDXR by subculturing it in DX-free medium for 20 passages.IN VIVO DOXORUBICIN-RESISTANT B16 MELANOMA LINE 225
monolayer cultures to 0.25% trypsin and
resuspension in serum-free medium. Only
suspensions containing single cells with >95%
viability, as determined by the trypan blue
exclusion, were injected. B16V cells were used at
about the 30th in vitro transplant, B16VDXR at
about the 70th and B16VR at about the 90th
transplant generation, the last 20 ones having been
done without DX. DX and cis-DDP were
administered i.v. once a week for 3 weeks starting 1
day after tumour implant. The longest and the
shortest tumour diameters were measured by caliper
twice a week and tumour weight was estimated
according to Geran et al. (1972). Each animal was
checked until death; at autopsy lungs were removed
and the number of metastases per lung were
counted with the aid of a dissecting microscope.
Three end points were used to assess the
antitumour activity.
1. The tumour growth delay (T-C), i.e. the
difference in number of days required for the
tumours to reach 1 g between treated mice and
controls; the significance (Student's t test) of the
difference of the tumour weights of treated and
control mice at 1 week after the last treatment
was also evaluated; usually a T-C >4 days
corresponded to a significant reduction of
tumour weight.
2. The percentage increase of median survival time
of treated mice compared to controls (% ILS)
(statistical significance evaluated by Student's t
test).
3. The metastasis efficiency i.e. the average number
of metastases of treated mice/average number of
metastases of control mice (statistical signifi-
cance evaluated by Mann-Whitney U test).
For colonization potential assay, cells harvested
from tissue culture, as previously described, were
injected i.v. in a 0.2ml volume in a lateral tail vein
of B6D2F1 mice. Viable tumour cells were also
mixed with 106 irradiated (10OGy) cells in order to
obtain more reproducible and meaningful results
for quantitative analysis of experimental metastatic
capacity (Hart et al., 1983) and heparin was also
added to reduce intravascular cell clumping
(Stackpole et al., 1985a). Three weeks after tumour
cell injection, mice were killed, the lungs removed
and the number of colonies per lung were counted
with the aid of a dissecting microscope.
Flow cytometric determination ofDNA content
The tumours (5-10mm diameter) were removed,
washed in 0.9% NaCl and minced with scissors to
remove the necrotic part from the vegetal part
which was used for DNA analysis. Cells were then
harvested with trypsin-EDTA, washed in PBS
and resuspended in a solution of 0.1% sodium
citrate containing 50jugml - I propidium iodide
(Calbiochem-Behring Corp., La Jolla, CA, USA),
50Uml-I RNAse A (Sigma, St. Louis, MO, USA)
and 0.05% triton X-100 (Calbiochem-Behring
Corp.). Mouse thymocytes used as a reference for
the diploid value were processed in the same way.
Flow cytometric measurements were performed
with a microscope-based flow cytofluorimeter
(Leitz, Wetzlar, West Germany), equipped with a
1OOWHg lamp as the source of excitation light.
Excitation and emission wavelengths were selected
by BG38 and BG12 excitation filters, a 580nm
chromatic beam splitter and a 610nm barrier filter.
Fluorescence intensity, proportional to DNA
content, was recorded by a multichannel analyzer
(Spectroscope Modular 8000, Laben, Milan, Italy)
and displayed as fluorescence histograms.
Pharmokinetics studies
B6D2F1 mice with s.c. implanted cells were treated
i.v. with DX 6.6mgkg-1 when the tumours were
palpable (5-10mm diameter). Three animals per
point were killed with ether at different times after
treatment. Tumours were removed, rinsed in cold
saline and stored at -70°C until drug analysis. DX
was assayed from the tumours as already reported
(Formelli et al., 1986). Briefly, tumour homogenates
were deproteinized by CH3CN-phosphate buffer
and drug released from DNA by AgNO3 and
analyzed by high performance liquid chroma-
tography (HPLC) into a C18 reverse phase column
(Perkin Elmer HS-5) with CH3CN: 0.01 M
KH2PO4pH 3.8 (34:66) as mobile phase. Detection
was by fluorometry on a Perkin Elmer MPF44A
spectrofluorometer at 570nm excitation and 590nm
emission wavelengths.
Results
Dx-sensitivity ofB16 melanoma lines
The activity of DX administered to mice
transplanted s.c. with 106 cells of the original B16
melanoma and of the in vitro obtained lines was
tested in parallel in several experiments in order to
have a 'head-to-head' comparison. DX was
administered i.v. at a dose of 6.6mgkg-1 starting
from day 1 after tumour implant once a week for 3
weeks. This dose was chosen as the maximal
tolerated dose with this schedule of treatment on
non tumour-bearing B6D2F1 mice, and as the
optimal therapeutic dose against B16 melanoma
from a dose-response study (data not shown).
The results are reported in Table I; only one
experiment was performed with the B16VR line.226 F. FORMELLI et al.
Table I Antitumour activity of DX in mice bearing B16 melanoma lines
In vitro
DXa Tumour growth Metastasis efficiency
Line (ngml-1) RIb delay (T-C)C %ILS(T!C)d (T/C)e Latency (days)'
B16 - 17 (14-23) +24 (12-30) 0.44 (0.04-0.90) 8 (7-12)
B16V - 11 (8-12) +44 (15-73)9 6.00 (0.50-20.00)h 9 (7-12)
B16VDXR 50 15 9 +13 2.80 12
100 69 9.7 +42' 9.30' 11
420 137 2 -3 0.80 18
420 275 4 +4 1.28 24
420 260 0 +16 0.31 24
420 310 2 -9 1.20 19
B16VR 0 428 0 +18 3.7/0 17
For B16 and B16V the average and the range (in parenthesis) of the results of 5 experiments are reported. DX
concentrations in which cells were cultured in vitro. B16VR was cultured without DX during 20 transplants. bID50 on
B16VDXR/ID50 on B16V. cDifference in number of days required for tumours to reach 1 g between treated mice and
controls. T-C>4 days corresponds to a significant tumour growth reduction. dPercentage increase of median survival time
of treated mice compared to controls. eAverage number of metastases of treated mice/Average number of metastases of
control mice. fAverage time for tumours to become palpable (_0.1 g) in non-treated animals. gThe results were significant
for P<0.05 in 4/5 experiments and for P<0.01 in 1/5 experiments by Student's t test. hThe results were significant for
P<0.05 in 1/5 experiments by Mann-Whitney U test. 'P<0.01 by Student's t test. 'P<0.01 by Mann-Whitney U test.
DX treatment caused a significant delay of the
growth of B16 melanoma and of the Bl6V line.
This growth delay resulted in a significant increase
of survival time only in animals bearing the in vitro
derived B16V line, possibly due to the fact that this
line has a lower spontaneous metastasizing capacity
compared to B16 (see Table II). DX treatment
caused a reduction of lung metastases in animals
bearing melanoma B16 while in animals bearing the
B16V line an increase in metastasis efficiency was
observed most likely as a consequence of their
increase in life span.
The B16VDXR line, at different in vitro RI
values during induction of resistance was also tested
in the same experiments, to assess the relationship
between in vitro and in vivo resistance to DX. The
B16VDXR line was sensitive to DX treatment when
the in vitro RI was as high as 69 while at higher RI
values, DX treatment had no effect either on
tumour growth or on survival time. The B16VR
line, derived from B16VDXR after 20 in vitro
passages in the absence of DX, was found more
resistant in vitro than the original B16VDXR line
and it was also resistant in vivo. An increase in
metastasis efficiency was sometimes observed in
animals bearing the two resistant lines which was
not associated with the increase in survival time. In
Table I the latency periods of non-treated mice
injected with the four tumour lines are also
reported. The two DX-resistant lines had a longer
latency compared to the two sensitive lines and, in
particular, the latency of B16VDXR was longer
than the latency of B16V, but only when the
tumour was resistant to DX treatment (in vitro RI
higher than 69).
All the experiments reported in this paper refer
to the B16VDXR line were run with cells grown
in vitro in medium containing 420ngml-1 and
showing an in vitro RI of -200.
Biological properties ofBJ6 melanoma lines
The main biological properties after s.c. inoculum
in B6D2F1 male mice of B16 melanoma and of the
three lines obtained from it are summarized in
Table II. The resistant lines, compared to the in
vitro sensitive one (B16V), led to the appearance of
tumours with longer latency and with higher
variability among the single animals in all the
experiments. As a consequence of the longer
tumour-free interval, the survival time of mice
bearing the resistant line was longer and they died
with slightly larger tumours (12.8+3.7 vs.
9.5+3.6g). The doubling time of the B16VDXR
line was slightly higher, with a higher standard
deviation, and the metastasizing capacity, evaluated
at death, slightly lower compared to the sensitive
line. All the in vitro obtained lines had lower
metastasizing capacity compared to the original
tumour and this difference does not seem to be due
to survival duration. The two in vitro obtained lines
had a histological pattern similar to the original
tumour formed by epithelial cells with a minimal
percentage of spindle cells. The tumourigenic dose
50 of the resistant line was slightly lower compared
to the sensitive line.IN VIVO DOXORUBICIN-RESISTANT B16 MELANOMA LINE 227
Table II Biological properties
B16 B16V B16VDXR B16VR
After s.c. inoculum of 106 cellsa
Latency (days)b 7.9+2.1 9.3+ 1.8 19.5+4.8*** 17.1 +9.3
Doubling time (days)c 3.0+2 1.7+0.8 2.8+ 1.3 1.7+0.7
Lung metastasis (%)d 70 48 28 0
Lung metastasis (No.)e 8 (0-30) 0 (0-20) 0 (0-22)
Median survival time (days) 34 (22-39) 28 (14-40) 41.5 (26-69)*** 28 (13- >62)
Histology Epithelioid Epithelioid Epithelioid ND
Tumourigenic dose 50f ND 0.97 x 105 1.3 x 105 ND
aThe results are the average +s.d. and the median with, in parenthesis, the range obtained from control groups each
one consisting of 8-10 animals of 5, 5, 4 and 1 experiments, respectively of B16, B16V, B16VDXR and B16VR. Student's t
test has been applied to the data of the different groups of B16V and B16VDXR when there was homogeneity of variances
(latency and survival time). bTime for tumours to become palpable (_ 0.1 g). cCalculated from single tumour growth curves
from 500 to 1000mg. dPercentage of animals with metastasis. eMedian number of metastases per animal and, in
parenthesis, range. fEvaluated from the number of mice developing tumours on the total number of mice injected s.c. with
different cell inocula.
***P<0.001 Student's t test vs. B16V; ND=not detected.
Since B16VDXR cells had shown in vitro (Supino
et al., 1986) a higher DNA content compared to
the B16V cells, we checked if this characteristic was
maintained after s.c. growth in vivo and how the
DNA content of both lines differed from the
parental B16 melanoma.
The histograms of fluoresence intensity,
proportional to the DNA content of cells from s.c.
grown B16 (a), B16V (c) and B16VDXR (d)
tumours, are shown in Figure 2 together with the
fluorescence distribution of mouse thymocytes (b)
measured for reference to the diploid value.
Cells from the parental B16 melanoma show a
bimodal fluorescence distribution where the first
peak is similar to the G1 diploid value of
thymocytes, while the second peak has the position
of cells in G2 +M phase. B16V cells show a pattern
similar to B16 cells while B16VDXR cells, as found
in vitro (Supino et al., 1986), show besides a first
and a second peak similar to those of sensitive cells,
a third peak shifted towards higher values (hyper-
tetraploid).
In order to better characterize the in vivo
behaviour of the four tumour lines, we also tested
their colonization capacity by injecting different
numbers of tumour cells i.v. and killing the animals
three weeks later (Table III). The two DX-resistant
lines had a lower colonization capacity compared to
the two DX-sensitive lines (B16 and B16V). It
should be noted that B16V caused a high number
of lung nodules and of extrapulmonary colonies as
well. Because of the longer latency period after s.c.
inoculum of B16VDXR compared to B16 and
B16V, some animals injected i.v. with 10o
B16VDXR cells were killed also 6 weeks after
tumour injection and no colonies were found.
Lack of cross-resistance of the B16VDXR line with
cis-DDP
To see whether there was cross-resistance between
DX and another anticancer agent known to have a
different mechanism of action, the activity of cis-
DDP administered i.v. at the maximal tolerated
dose, (4mgkg-1) starting on day 1 after tumour
implant once a week for 3 weeks was tested in
animals transplanted s.c. with 106 cells of the B16V
and the B16VDXR lines (Table IV). Cis-DDP
caused a significant delay of the growth of both
tumour lines, but it prolonged survival only in
animals bearing the resistant line, a finding which
resulted in an increase in metastases. In the
experiments carried out with animals bearing the
resistant line, cis-DDP treatment caused a very high
percentage increase of the median survival time
(107%) in one experiment and 3 long term
survivors out of 10 in the other one. These data
suggest that the B16VDXR line is not cross-
resistant but, on the contrary, is collaterally
sensitive with cis-DDP.
Stability ofthe resistance phenotype
B16VDXR cells have been shown to maintain
resistance to DX during 50 in vitro passages in
absence of the drug (Supino et al., 1986). To check
the in vivo stability of DX-resistance phenotype, the
two resistant lines B16VDXR and B16VR were
transplanted in vivo when the tumour diameter was
5-10mm and their sensitivity after s.c. transplant of
106 cells to DX treatment (6.6mgkg-' from day 1
once a week for 3 weeks) was checked at different
transplant generations. Table V shows that the two228 F. FORMELLI et al.
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Figure 2 Distribution of fluorescence intensity of DNA-propidium iodide in B16, B16V, B16VDXR tumour.
(a) B16: peaks at channels 124 and 243; (b) Mouse thymocytes: peaks at channels 129 and 249; (c) B16V:
peaks at channels 123 and 240; (d) B16VDXR: peaks at channels 127, 253 and 370.
lines became very quickly sensitive to DX: DX
treatment significantly increased the tumour growth
delay and the survival time of animals bearing the
fifth transplants of both lines. Among the checked
parameters of growth of the two lines, the latency
of the tumour varied in the serial transplants in vivo
and in particular it became shorter and similar to
that of the DX-sensitive line with the increase in
the number of transplants.
To check the outcome of DX chemotherapy in
mice bearing both sensitive and resistant tumours
and how resistant and sensitive cells in the same
tumours influence the growth and the sensitivity of
the whole tumours, mice were transplanted s.c.
either with B16V cells in one flank and B16VDXR
on the other flank or with 50% B16V cells and
50% B16VDXR cells in the same flank and treated
with DX (Table VI). In animals bearing separate
tumours, each tumour behaved as if it was in
separate animals i.e. the resistant tumour had a
longer latency, compared to the sensitive one, and,
differently from the sensitive one, its growth was
not delayed by DX. As a whole it should be noted
that DX treatment caused a significant increase of
survival time with a consequent increase in
metastasis incidence. In mice bearing tumours
consisting of 50% sensitive and 50% resistant cells,
the latency was similar to that of the sensitive line
and this may be due to the fact that the growth of
B16V cells, which have shorter latency, masks the
latency of B16VDXR cells. In animals treated with
DX, the growth of the tumour was delayed 5 days
and the survival time was significantly longer
compared to non-treated animals.
Therefore, these results suggest that DX-resistant
cells do not influence the sensitivity of sensitive cells
when present in two separate tumours or in similar
percentages in the same tumour.
a
100
n
0
0 L- o
a)
E
c
*' 100
C)
cc
c
0
0 500IN VIVO DOXORUBICIN-RESISTANT B16 MELANOMA LINE 229
E04 ,~~~~~~~~~~~~~~~oX
.0
3C ~ ~ 0 II 0E
00
0
oo~~~~~~~~a
Co)~~~~~~~~~~~~C
0
lz¢ z S t;09
C4)
o ~~~~~~~~n~ A) C
o C~~~-~0 ~ WJ 00
U -~~~A-4-
- -
x x x x x x
0~~~m_a230 F. FORMELLI et al.
Table IV Antitumour activity of cis-DDP in B16V and B16VDXR bearing mice
Metastasis
Tumour growth efficiency
delay (T-C)a O%ILS (T/C)b (TIC)0 LTSd
Line Exp. I Exp. 2 Exp. I Exp. 2 Exp. I Exp. 2 Exp. I Exp. 2
B16V 12 4 -25 -4 ND 0/7.1 0/10 0/10
B16VDXR 8.5 6 + 107** +40** ND 5.25 0/10 3/10
aDifference in average number of days required for tumours to reach 1 g between treated mice and controls;
bPercentage increase of median survival time of treated mice compared to controls; 'Average number of
metastases of treated mice/Average number of metastases of control mice; dLong term survivors at 3 months;
**P<0.01 Student's t test; ND=not detected.
Table V Antitumour activity of DX against in vivo
B16VDXR and B16VR
serial transplantation of
Metastasis
In vivo Tumour growth % ILS efficiency Latency
Line transplants delay (T-C)Q (T/C)b (TIC)Y (days)d
B16VDXR 1st 1 +13 10.6t 12
2nd 3.5 +32* 2.24 13
5th 11 + 119* 43-5t 9
B16VR 1st 0 +18 3.7/0 14
3rd 2.5 +9 1.04 9
5th 4 +42* 5.43t 8
a,bc cSee Table IV; dAverage time for tumours to become palpable (- 0.1 g) in non-
treated animals; *P<0.05 Student's t test; tP<0.05 Mann-Whitney U test.
Table VI Antitumour activity of DX in mice bearing both B16V and B16VDXR
lines
Metastasis
Tumour growth % ILS efficiency Latency
Lines Exp. delay (T-C)' (TIC)b (TIC) (days)d
B16V 1 8 +32** 2.3 12
and
B16VDXR 2 18
50%0 B16V 2 5 +62*** 1.17/0 12
plus
5000 B16VDXR
In experiment 1, 106 cells B16V were inoculated s.c. in one flank and 106 cells
B16VDXR were inoculated s.c. in the other flank of the same animal. In
experiment 2, 5 x 105 cells B16V were admixed with 5 x 105 cells B16VDXR and
inoculated s.c. in one flank. DX treatment: 6.6mgkg-1 i.v. from day +1,
1 wk x 3wks. a b c dSee Table IV. **P<0.01; ***P<0.001 Student's t test.IN VIVO DOXORUBICIN-RESISTANT B16 MELANOMA LINE 231
DXpharmacokinetics in B16V and B16VDXR lines
In order to understand whether DX-resistance was
O = m due to different pharmacokinetics in the tumour,
0*
C o o. °. o; DX concentrations were evaluated in B16 and the
+ +I ++1 'j two tumour lines at different times after i.v.
C' s Q administration (Table VII). No DX metabolites
0 .= were found in the two lines at all the time points
examined. A great variability in DX concentrations
a 0 during the first 6h after treatment was found both
in the B16 and the B16VDXR lines. In spite of this
variability, drug levels were rather similar. Then the
o n oIt o o orelease of the drug was quicker from the resistant
._ ^ v line compared to the two sensitive ones since drug
ed X =3 Xconcentrations were significantly lower.
+E+1+1 < o oo a:Effect of the increase infrequency ofDX
;>N administration
The retention of DX being lower in the resistant as
Cd compared to the sensitive line, we checked if a
1) O £ 00 'IC more frequent treatment would also be effective 'IC cn o It o o = against the B16VDXR line. No increase in DX
00m +1 C., +1 e so =activity against the resistant line was obtained by
r. oN xo.: = increasing the frequency of DX administration
> O0t (4mgkg-1 on days 1, 4, 7, 9 vs. 6.6mgkg' on
days 1,8, 15) (data not shown).
00~~ EOo v Discussion
Xq , r m >The resistant line of B16 melanoma described in
> +1 -O xm°this paper shows, when first transplanted in vivo,
resistance to DX treatment which is effective, as
-o i> Y :,, assessed from the growth of the tumour and the
cq O >: o , <, Qsurvival time, on B16 melanoma and on the line
> +1 +1 m0 Z oc obtained in vitro (Bl6V), from which the resistant
m^ _ <,, X = line was derived.
u E
.5 As reported for other murine tumours (Schabel et
al., 1983), no cross-resistance was found for this
tumour line with cis-DDP. The 2-fold greater in
vitro cis-DDP sensitivity of the resistant line
o +- o v compared to the sensitive one (Supino et al., 1986)
c-i ci-N t = Xand the marked increase in survival time together
'8 a C Owith the presence of 3/10 long term survivors after
o ° xvm cis-DDP treatment in animals bearing the DX-
X t o - resistant line, suggest a collateral sensitivity of the
:.t +l: +1 =; .= <,,B16VDXR line to cis-DDP. The reduction in
_o z c survival time after cis-DDP treatment in animals
r -i -^ N '+ bearing the B16V line, in spite of the effect on
tumour growth, suggests a different toxicity of cis-
DDP in mice bearing different tumours, a finding
which might be due to a higher toxic
- may be
cachetic - effect of the sensitive line on the host
< o. X t °compared to the resistant one. Similar higher
£ > > ad so Vtoxicities have been reported for cis-DDP and other
m, m m m;anticancer drugs in mice bearing the ovarian
reticular cell sarcoma M5076 compared to the
cyclophosphamide resistant line (D'Incalci et al.,
1983).232 F. FORMELLI et al.
The main biological properties that characterize
the B16VDXR line in vivo compared to the parent
line B16V are the longer latency period with
consequent longer survival time and the lower
colonization capacity, all features which go along
with lower malignancy as reported for other drug-
resistant tumours (Biedler et al., 1983). The longer
latency of the B16VDXR line correlates with the in
vitro longer doubling time (25 vs. 15h) (Supino et
al., 1986) and this might be responsible for the
different sensitivity to both DX and cis-DDP. In
fact it has been reported that while rapidly growing
tumours are more sensitive to DX than slowly
growing tumours, the opposite is true for cis-DDP
(Mattern et al., 1981). The only slight differences
found in the growth rates of the two tumour lines
after they had become palpable is probably due to
the very short doubling times of the two lines, and
to the short experimental range time of tumour
measurements. Extrapolation of the experimental
data by Gompertz analysis is in progress.
The fact that B16VDXR showed after in vivo
growth the same higher DNA content compared to
the sensitive line B16V found in vitro (Supino et al.,
1986), indicates that no cell selection occurred
during in vivo growth. Similarly no selection seems
to have occurred in the sensitive line B16V obtained
by growing the parental B16 melanoma in vitro.
Karyotype analyses of the two lines are in progress
in order to better understand if this modification is
directly related to the drug-resistant phenotype
since double minute chromosomes and homo-
genously staining regions have been found in
different multidrug resistant cell lines and have
been associated with gene amplification (Riordan &
Ling, 1985). As far as the DNA content in resistant
lines compared to the sensitive ones is concerned,
increase (Parsons & Morrison, 1978) or decrease
(McMillan et al., 1985) in chromosome number and
similar DNA content (D'Incalci et al., 1983) have
been reported.
The finding that B16V and B16VDXR lines have
similar spontaneous metastatic behaviour but
different colonization capability extends similar
observations of lack of coincidence of the two
properties as reported for B16 melanoma
(Stackpole, 1981) and other murine tumours (Price
et al., 1984). The lower colonization potential of the
resistant line is directly related to the cloning
efficiency which has been found to be 10 times
lower for the resistant line (Supino et al., 1986) and
confirm similar findings on B16 melanoma
subclones (Stackpole et al., 1985b). Such a
correlation does not exist between the cloning
efficiency and the tumourigenicity of these two lines
as already reported for B16 melanoma cells in
culture (Kreider & Schomayer, 1975). In addition it
should be noted that, at variance with what has
been reported for other resistant tumour lines
(Biedler et al., 1975; Biedler et al., 1983) only a
slight decrease in tumourigenic potential is
associated with development of resistance in our
line.
The enhancement in metastasis formation not
associated with an increase in survival time,
sometimes observed in DX treated mice bearing the
resistant lines, is an interesting finding with
potentially important clinical implications. This
unfavourable result might be due to the immuno-
suppressive effect of chemotherapy on moderately
or markedly antigenic tumours (Elbe et al., 1973;
Nowak et al., 1973). In fact, it has been reported
that treatment with anticancer drugs may lead to
induction of new antigens on tumour cells (Nicolin
et al., 1972).
The analysis of the relationship between the
degree of resistance in vitro and the sensitivity to
DX treatment in vivo, show that the B16VDXR line
retained significant responsiveness in vivo in spite of
a RI value of 69 and this argues about the relation-
ship between in vitro and in vivo resistance results.
From the results obtained in our study this dis-
crepancy might be explained by the latency
differences between sensitive and resistant cells with
consequent in vivo predominance of sensitive cells,
with shorter latency, probably still present in the
resistant line at that particular RI. This possibility
is supported by the fact that if resistant cells were
inoculated together with similar percentages of
sensitive cells, the resultant tumour behaved as if it
was sensitive both in terms of latency and
sensitivity.
The loss also of the resistant phenotype during
few in vivo transplants might be due to latency
differences between sensitive and resistant cells and
to the procedure used for tumour propagation since
each transplant has been performed few days after
the tumours had become palpable, i.e. when most
likely sensitive cells with shorter latency were
replicating.
Our results on DX pharmacokinetics on the
resistant line confirm the data obtained in vitro on
several rodent and human tumour cell lines
(Giavazzi et al., 1983; Dan0, 1983; Inaba et al.,
1979; Howell et al., 1984; Rogan et al., 1984) in
which the induction of DX-resistance is associated
with decreased DX retention. The lack of activity
of DX against the resistant line even if administered
more frequently, suggests that decreased drug
retention is probably only one component of
resistance. In fact, B16VDXR cells have also shown
when incubated with DX in vitro, a different drug
intracellular distribution with lower nucleus/
cytoplasm ratio compared to the sensitive cells
(Supino et al., 1986).
In conclusion, our results obtained with this cellIN VIVO DOXORUBICIN-RESISTANT B16 MELANOMA LINE 233
line, which when first transplanted in vivo shows
resistance to DX treatment, indicate this model
to be suitable for in vivo studies of the mechanisms
of resistance to DX and for selecting non-
cross-resistant drugs and drugs able to circumvent
DX-resistance.
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